Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Vanguard Group Inc. cut its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 2.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,063,135 shares of the company’s stock after selling 68,467 shares during the quarter. Vanguard Group Inc. owned approximately 4.13% of Kiniksa Pharmaceuticals International worth $118,942,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $20,349,000. Qube Research & Technologies Ltd lifted its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Rubric Capital Management LP grew its stake in Kiniksa Pharmaceuticals International by 15.6% in the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after buying an additional 447,536 shares during the last quarter. Finally, Squarepoint Ops LLC raised its stake in Kiniksa Pharmaceuticals International by 186.2% during the second quarter. Squarepoint Ops LLC now owns 416,572 shares of the company’s stock valued at $11,527,000 after buying an additional 271,005 shares in the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of recent research reports. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target on the stock. Wedbush upped their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $47.27 on Thursday. The firm has a market capitalization of $3.58 billion, a P/E ratio of 63.88 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52-week low of $18.25 and a 52-week high of $49.12. The company’s 50 day simple moving average is $43.16 and its 200-day simple moving average is $40.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. The company’s revenue for the quarter was up 65.0% on a year-over-year basis. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $41.51, for a total transaction of $835,554.79. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at approximately $520,784.46. This trade represents a 61.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09. Following the transaction, the chief financial officer directly owned 31,086 shares in the company, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 123,623 shares of company stock worth $5,236,389. 53.48% of the stock is owned by corporate insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.